Lineage Cell Therapeutics: OpRegen Makes It A Viable Speculative Buy [Seeking Alpha]
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Seeking Alpha
Looking ahead, their GAlette Phase 2a trial is enrolling, which could further validate the rest of their portfolio's potential. LCTX's pipeline also has OPC1 for spinal cord injury. Its preclinical R&D includes ANP1, PNC1, RND1, and ILT1. Overall, LCTX is a bet on an interesting allogeneic off-the-shelf cell therapy platform. However, it's a bit expensive at these levels. Hence, I feel a speculative “Buy” makes sense for now, but it's contingent on how their 2026 catalysts play out. wildpixel/iStock via Getty Images Lineage Cell Therapeutics ( LCTX ) is a regenerative medicine company that uses its platform for "pluripotent" stem cells. The idea is to generate specialized, off-the-shelf human cells to replace damaged tissue in organs. For example, it could help regenerate the eyes, spinal cord, auditory This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate a
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Dimension Bio Announces Inaugural Clinical and Scientific Advisory BoardsPR Web
- Lineage Cell Therapeutics Inc (LCTX) Q3 2025 Earnings Call Highlights: Strategic Partnerships ... [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics GAAP EPS of -$0.13 misses by $0.10, revenue of $3.68M beats by $1.38M [Seeking Alpha]Seeking Alpha
- Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire
- Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025Business Wire